Mode
Text Size
Log in / Sign up
N/A N=59 Randomized Double-blind Treatment

Study to Compare Laser Assisted New Attachment Procedure (LANAP) to Traditional Treatments of Chronic Periodontitis

Chronic Periodontitis

Enrolled (actual)
59
Serious AEs
0.0%
Results posted
Oct 2015
Primary outcome: Primary: Gain in Clinical Attachment Level of Periodontal Tissues — 1.361; 2.387; 1.180; 2.329 mm

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
LANAP (Device)
Age
Adult, Older Adult · 25+ yrs
Sex
All
Sponsor
Institute for Advanced Laser Dentistry
Primary completion
Mar 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Gain in Clinical Attachment Level of Periodontal Tissues
1.361; 2.387; 1.180; 2.329; 1.347; 2.061
SECONDARY
Change in Probing Depth (PD)
1.674; 1.834; 1.550; 1.084; 1.888; 1.831
SECONDARY
Change in Bleeding on Probing (BOP)
-24.9; -22.9; -23.7; -18.0; -23.0; -20.4
SECONDARY
Change in Gingival Index
-1.28; -1.30; -1.28; -1.14; -1.29; -1.27
SECONDARY
Discomfort
10; 19; 4.4; 3.5

Summary

The purpose of this study is to compare the Laser Assisted New Attachment Procedure (LANAP protocol) using the Free-running (FR) Pulsed Neodimium: Yttrium aluminium garnet (Nd:YAG) laser to Scaling and Root Planing (SRP) alone, Modified Widman Flap (MFF) surgery, and Coronal Debridement (CD) alone with respect to periodontal clinical attachment level gain.

Eligibility Criteria

Inclusion Criteria

  • Subjects will have chronic adult periodontitis as characterized by all four quadrants of the mouth.
  • Subjects will be 25-75 years of age.
  • Subjects will be able to follow verbal and/or written instructions, perform Oral Hygiene according to the protocol, and return to the center for specified study visits.
  • Subjects must have had no subgingival scaling instrumentation including scaling and root planing, regular periodontal maintenance procedures or any subgingival cleaning 6 (six) months stopped), and not using or taking any nicotine product.
  • Subjects will have clinical and/or radiographic evidence of subgingival calculus in each quadrant.
  • Subjects have no more than one missing tooth per quadrant, excluding 3rd molars.
  • Subjects will be able to sign the informed consent form.

Exclusion Criteria

  • Subject receiving subgingival scaling instrumentation including scaling and root planing, regular periodontal maintenance procedures or any subgingival cleaning less than twelve (12) months prior to Baseline examination.
  • Subjects receiving periodontal surgery of any type prior to Baseline examination.
  • Subjects with dental implants.
  • Subjects with a compromised heart condition, history of rheumatic fever, or joint replacement requiring prophylaxis.
  • Subjects having taken systemic cancer therapy and/or radiation therapy at any time
  • Subjects with clinically significant acute or concurrent illness
  • Subjects with clinically significant chronic illness.
  • Subjects with a disease of the connective tissue.
  • Subjects taking medications which are likely to cause gingival hyperplasia, within ONE MONTH prior to Baseline examination
  • Subjects taking antimicrobials within ONE MONTH prior to Baseline examination
  • Subjects taking non-steroidal anti-inflammatory drugs at a therapeutic dose within the TWO WEEKS prior to Baseline examination.
  • Subjects taking steroids of any kind within ONE MONTH prior to baseline examination.
  • Subjects taking continuous low doses of tetracycline within THREE MONTHS prior to Baseline examination
  • Subjects taking an investigational drug within TWO MONTHS prior to Baseline examination
  • Subjects taking or having taken bisphosphonates of any kind for any reason.
  • Female, nonsterile subjects who are pregnant or lactating.
  • Subjects who, in the investigator's opinion, would not comply with the study procedures.
  • Smokers of any type or former smokers and subjects that take or use any nicotine product.
  • Excessive alcohol intake.
  • No current restorative or endodontic treatment needs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01282229). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search